



Press release
February 7, 2012
Gothenburg

Further lawsuits filed against Vitrolife's American subsidiary regarding Perfadex

Further lawsuits have been filed against Vitrolife with regard to Perfadex. As the products were sold before the distribution of XVIVO Perfusion, Vitrolife will also handle the lawsuits in the future.

During the third quarter information was received that a lawsuit had been filed against Southwest Transplant Alliance and the University of Texas together with Vitrolife's American subsidiary, in which damages were being claimed by relatives of a patient who had died in 2010 in connection with a lung transplant. During the fourth quarter two similar lawsuits were filed against the same parties.

Perfadex is an organ preservation solution that has been approved by the FDA for the American market since 2001 and has been marketed by Vitrolife since then up until September 2012. As from October 2012 Perfadex has been marketed by XVIVO Perfusion on the American market. The solution is today used by all lung transplant centers in the USA and has so far been used in thousands of lung transplants. As the products were sold before October 2012, XVIVO Perfusion is not involved in the lawsuit.

The lawsuits have not yet gone to trial, but are at an early stage where evidence regarding the claims is to be presented in a so-called discovery process. The lawyers representing Vitrolife and its insurance company make the assessment that, on the basis of the information that has come to light at present, Vitrolife has a good chance of winning if the lawsuit goes to trial.

February 7, 2013

Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO

For further information, please contact

Magnus Nilsson, CEO, tel: +46 31 788 21 50, e-mail: magnus.nilsson@xvivoperfusion.com

Christoffer Rosenblad, CFO, tel: +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com

For further information on XVIVO Perfusion's business, please refer to the company's website, www.xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on February 7, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.